Product Data Sheet

Cas No.:	78214-33-2	Cat. No:	PC64080
Product Name:	Ginsenoside Rh2.		
Product synonym:	人参皂苷 Rh2;人参皂苷-RH2;(R型)人参皂苷RH2;人参皂荚RH2;人参皂苷 S-RH2;人参皂苷RH2(标准品);人参皂甙 Rh2;(20S)人参皂苷 Rh2;(S型)人参皂苷Rh2;20(S)-人参皂苷Rh2;20(S)-人参皂苷-RH2;20(S)-人参皂苷-RH2,20(S)-Ginsenoside-RH2,植物提取物,标准品,对照品;S-人参皂苷Rh2;人参皂甙 Rh2 Ginsenoside Rh2;人参皂苷 Rh2 (S-FORM)(AS);人参皂苷 Rh2 (S-FORM)(P);人参皂苷Rh2 对照品标准品;人参皂苷Rh2 标准品;人参皂苷Rh2（S）;人参皂苷Rh2(人参皂苷S- Rh2 、20(S)-人参皂苷RH2);人参皂苷Rh2对照品;分析对照品		
Chemical name:	Ginsenoside Rh2.		
MF:	C36H62O8	FW:	622.8727
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax：	-	Formulation：	-
Solubility :			
SMILES :	O([H])C1([H])C([H])([H])C2([H])[C@@]3(C([H])([H])[H])C([H])([H])C([H])([H])C([H])(C(C([H])([H])[H])(C([H])([H])[H])C3([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]2(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([C@](C([H])([H])[H])(C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O[H])C21[H])OC1([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])O[H])O1)O[H])O[H])O[H]		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Ginsenoside Rh2 诱导 caspase-8 和 caspase-9 活化。Ginsenoside Rh2 以多途径方式诱导癌细胞凋亡。Ginsenoside Rh2 诱导 caspase-8 和 caspase-9 活化。Ginsenoside Rh2 以多途径方式诱导癌细胞凋亡。

生物活性	Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
IC50 & Target[1][2]	Caspase-8 Caspase-9

体外研究(In Vitro)	Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC50 value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC50 values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC
体内研究(In Vivo)	A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P<0.05). The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent (P<0.05).Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	Powder； -20°C； 3 years; 4°C； 2 years；
溶解度数据	体外研究: DMSO : 50 mg/mL(80.27 mM;Need ultrasonic) 配制储存液